{
    "Trade/Device Name(s)": [
        "CEDIATM Heroin Metabolite (6-AM) Assay"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K231007",
    "Predicate Device Reference 510(k) Number(s)": [
        "K192943"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "August 11, 2023",
    "Summary Letter Received Date": "August 15, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "6-Acetylmorphine",
        "Heroin"
    ],
    "Specimen Type(s)": [
        "Human Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Horiba Yumizen C1200"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "CEDIA technology"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for CEDIATM Heroin Metabolite (6-AM) Assay, a homogeneous enzyme immunoassay for detection of heroin metabolite in human urine",
    "Indications for Use Summary": "For in vitro qualitative and/or semi-quantitative determination of heroin metabolite (6-AM) in human urine at 10 ng/mL, as a rapid screening procedure using clinical chemistry analyzers by trained professionals; results require confirmatory testing.",
    "fda_folder": "Toxicology"
}